Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)

The stock has had quite the run following Rezdiffra's 2024 approval by the FDA.

There is a key difference between these two biotechs.

The pharmaceutical leader looks poised to stop the bleeding.

The company's worst days might be behind it.

They haven't peaked yet.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake.

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating.

Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in

Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.